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Objectives. In this multicenter, randomized trial we evaluated
whether stent implantation after successful recanalization of a
chronic coronary occlusion reduced the incidence of restenosis.
Background. Percutaneous transluminal coronary angioplasty
(PTCA) in chronic total occlusions is associated with a higher rate
of angiographic restenosis and reocclusion than PTCA in subtotal
stenoses. Preliminary reports have suggested a decreased resten-
osis rate after stent implantation in coronary total occlusions.
Methods. We randomly assigned 110 patients with recanalized
total occlusion to Palmaz-Schatz stent implantation, followed by 1
month of anticoagulant therapy versus no other treatment. The
primary end point was the minimal lumen diameter (MLD) of the
treated segment at follow-up, as determined by quantitative
angiography at a core laboratory.
Results. Repeat coronary angiography was performed 9 months
after the procedure in 88% of patients. The MLD (mean 6 SD) at
follow-up was 1.74 6 0.88 mm in patients assigned to stent
implantation and 0.85 6 .75 mm in patients assigned to PTCA
(p < 0.001). Stent implantation was associated with a lower
incidence of restenosis (defined as diameter stenosis >250% at
follow-up) (32% vs. 68%, p < 0.001) and reocclusion (8% vs. 34%,
p 5 0.003) than balloon PTCA. Likewise, stent-treated patients
had less recurrent ischemia (14% vs. 46%, p 5 0.002) and target
lesion revascularization (5.3% vs. 22%, p 5 0.038), but experi-
enced a longer hospital stay.
Conclusions. Palmaz-Schatz stent implantation after successful
balloon PTCA of chronic total occlusions improves the midterm
angiographic and clinical outcome and could be the preferred
treatment option in selected patients with occluded vessels.
(J Am Coll Cardiol 1998;32:90–6)
©1998 by the American College of Cardiology
Percutaneous transluminal coronary angioplasty (PTCA) in
chronic total occlusions has specific limitations. In this ana-
tomic subset, the primary success rate is lower, whereas cost,
fluoroscopy time and equipment use are higher than with
PTCA in subtotal stenoses (1–3). In addition, chronic total
occlusions that are successfully dilated have a higher rate of
angiographic restenosis than subtotal stenoses (4,5). Although
advances in PTCA technology and operator experience seem
to have increased the success rate, the rate of angiographic
restenosis does not appear to be lessened (3). Observational
studies (6–9) have reported that implantation of the Palmaz-
Schatz stent in chronic total occlusion was associated with a
high immediate success rate and a restenosis rate lower than
that reported for PTCA. Only one randomized trial (10) has
compared balloon PTCA with Palmaz-Schatz coronary stent
placement in selected patients with chronic total occlusion,
showing a significant reduction in restenosis in the stent group.
Accordingly, we performed a multicenter, randomized trial
to investigate whether Palmaz-Schatz stent implantation after
successful balloon PTCA in a chronic total occlusion could
improve the midterm angiographic and clinical results com-
pared with balloon PTCA alone.
Methods
Patient selection. The study included patients scheduled to
undergo PTCA of a chronic total occlusion at eight interven-
tional cardiology centers with experience in Palmaz-Schatz
coronary stenting. The study protocol was approved by the
institutional review board at each participating center.
Both absolute occlusions (Thrombolysis in Myocardial In-
farction [TIMI] flow grade 0), where no anterograde filling
beyond the lesion was visible, and “functional” occlusions
(TIMI flow grade 1) (11), where a faint, late anterograde flow
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with incomplete opacification of the distal vessel in the absence
of a discernible lumen channel, were included. The duration of
the occlusion was estimated from previous angiographic data
or from the date of a myocardial infarction in the distribution
of the occluded vessel. In the absence of these data, a
worsening of anginal status was utilized to estimate the dura-
tion of the occlusion. Written informed consent was obtained
from the eligible patients.
Inclusion and exclusion criteria. Patients symptomatic for
chest pain or demonstrating inducible ischemia in the territory
supplied by the occluded artery were selected for the study.
The patients were suitable candidates for coronary artery
bypass graft surgery. Patients with an acute myocardial infarc-
tion within 30 days or chest pain at rest within 7 days, as well
as patients with contraindication to aspirin or warfarin sodium,
were excluded. Total occlusions at a site of a previous PTCA
and occlusions ,30 days in duration were not considered.
Patients with significant left main disease were excluded.
Vessels ,3 mm in diameter or presenting severe tortuosity and
lesions .13 mm or involving a major side branch were also
excluded from consideration. In addition, evidence after re-
canalization of diffuse disease, additional stenosis .50% of the
lumen diameter in the distal segment and complex dissection
(type C to F according to Dorros et al. [12]) were exclusion
criteria. The evaluation of these angiographic criteria was
made by the investigators on visual inspection.
Randomization. The target occlusion was treated by con-
ventional balloon angioplasty. In some cases, the Magnum-
Meier system (Schneider AG, Bu¨lach, Switzerland) was used
(13). In case of successful recanalization, defined as restoration
of anterograde TIMI grade 2 or 3 flow with a residual stenosis
,50% of the lumen diameter by visual estimation, the angio-
gram was immediately evaluated to establish whether all the
angiographic inclusion criteria were met. The patients were
then randomized, by means of sealed envelopes, to undergo
stent implantation or no additional treatment.
Procedural protocol. All patients received aspirin (150 to
325 mg daily) and a calcium channel blocking agent starting at
least 24 h before PTCA. During the procedure, heparin was
given to maintain the activated clotting time .250 s.
In patients assigned to stent implantation, a standard
Palmaz-Schatz stent (two 7-mm segments connected by a
single 1-mm bridging strut) was manually crimped onto a
conventional balloon catheter, usually the same balloon used
to dilate the occlusion, and deployed to the target site. After
implantation, the stent was further dilated by the same or a
larger balloon to minimize the residual narrowing. Intravascu-
lar ultrasound imaging was not used. Four to 8 h after
hemostasis at the site of arterial access was achieved, oral
warfarin and heparin infusion were begun. The dosage was
adjusted according to the prothrombin time and the activated
partial thromboplastin time, respectively. Heparin infusion was
continued until an international normalized ratio of 2.5 to 3.5
was obtained. Warfarin was continued for 1 month and aspirin
indefinitely. Administration of intravenous low molecular
weight dextran during the procedure and oral dipyridamole
before or after the procedure was left to the investigator’s
choice.
In patients randomized to PTCA alone, further balloon
dilatations aimed to optimize the angiographic result were
allowed. Crossover to stent implantation was considered in the
case of worsening of the residual stenosis to .50% of the
lumen diameter. After the procedure, oral aspirin was pre-
scribed, but heparin or warfarin was not.
Follow-up. Patients were asked to return for clinical eval-
uation at 3, 6 and 9 months after the procedure. An exercise
test was scheduled at 9 months. Coronary angiography was
repeated at 9 months, or earlier if clinically indicated. An
unscheduled angiogram obtained before 6 months could sub-
stitute for the follow-up angiogram if either a revascularization
procedure of the target lesion was subsequently performed or
a diameter stenosis .50% by quantitative coronary angiogra-
phy was found.
Angiographic analysis. The cineangiograms were reviewed
at a central laboratory by an experienced cardiologist (G.T.)
not involved in patient recruitment and treatment. For quan-
titative analysis, three angiograms taken just before and just
after the procedure and at follow-up were considered for each
patient. In all cases, angiography was performed in two orthog-
onal views after intracoronary injection of 0.2 mg of nitroglyc-
erin. An end-diastolic frame in the projection best showing the
lesion severity was selected and digitized by means of a cine
video converter and a frame grabber mounted on a personal
computer. Quantitative analysis was performed by a validated
(14) edge detection algorithm (Intelligent Images QCA,
Genoa, Italy). In validation studies on Plexiglas phantoms (14),
this system was able to measure absolute dimensions with an
accuracy of 0.028 mm and a precision of 0.054 mm.
The untapered section of the tip of either a 7F or 8F
catheter was used for calibration. On the preintervention
angiogram, the diameter of the vessel proximal to the occlu-
sion was measured, and the minimal lumen diameter (MLD)
was assumed to be 0. On the follow-up and post-intervention
angiograms, the MLD and the interpolated reference diameter
(RD), the latter defined as the computer-calculated estimation
of the original coronary dimension at the site of the obstruc-
tion, were assessed. In case of a total occlusion at follow-up,
either absolute or “functional” according to the same criteria
Abbreviations and Acronyms
BENESTENT 5 Belgium and Netherland Stent study
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used for preintervention occlusions, the MLD was assumed to
be 0, and the diameter of the vessel proximal to the occlusion
was substituted for the RD.
The following indexes were derived from the MLD and RD:
Diameter stenosis (DS) was defined 1 minus (MLD divided by
RD). Late loss was defined as the postintervention MLD minus
the MLD at follow-up. Loss index was defined as late loss
divided by the postintervention MLD, indicating the fraction
of the lumen gain obtained with the procedure that is lost
during follow-up. MLD and RD are measured in mm.
Statistical analysis. The primary end point of the trial was
the MLD at follow-up. The secondary angiographic end point
was restenosis, defined as stenosis .50% of the lumen diameter
at follow-up.
Secondary clinical end points were major ischemic events
(death, myocardial infarction, coronary artery bypass graft
surgery, repeat angioplasty, target lesion revascularization),
symptomatic status at follow-up and hemorrhagic events (in-
tracranial bleeding or complications requiring vascular surgery
or blood transfusion). All evaluations were performed accord-
ing to the intention to treat principle.
We calculated that, assuming a reduction in the restenosis
rate from 50% (3) to 25%, with a sample size of 110 patients,
the study would have had the power of 0.80 to detect a
difference between the two groups with an alpha error of 0.05.
We also considered that the use of MLD as a continuous
variable, instead of a categoric approach (restenosis yes/no),
would increase the power of the study to detect a difference
between the two groups with the same sample size (15),
compensating for losses at follow-up.
Categoric variables are expressed as absolute numbers and
percent value. Continuous variables are expressed as mean
value 6 SD. Differences between groups were assessed with a
continuity-adjusted chi-square test for categoric variables and
with a two-tailed unpaired Student t test for continuous
variables; p , 0.05 was considered significant. Stepwise logistic
regression analysis (SAS procedure, release 6.11 for Windows)
was used to assess the relation between the MLD at follow-up
and multiple clinical and angiographic variables, including
demographics, coronary risk factors, symptom status, assigned
treatment, occlusion type and location, vessel size and post-
procedural angiographic data.
Results
Baseline and procedural data. The study included 111
patients enrolled from June 1992 to May 1995. One patient
assigned to balloon PTCA was subsequently excluded because
the treated lesion was found to be subtotal. Thus, the study
group included 56 patients assigned to stent placement and 54
patients assigned to balloon PTCA. The baseline clinical and
angiographic characteristics are shown in Tables 1 and 2. A
higher prevalence of previous myocardial infarction, single-
vessel disease and left circumflex coronary artery occlusion was
observed in the PTCA group, whereas the stent group had a
higher prevalence of hypercholesterolemia and right coronary
artery occlusion. However, these differences were not statisti-
cally significant. Other baseline clinical and angiographic char-
acteristics were well matched.
In five patients assigned to stent placement (8.9%), implan-
tation of a second stent was required. One patient assigned to
balloon PTCA experienced intraprocedural reocclusion of the
dilated lesion and underwent successful stent implantation. In
four patients in the stent group and five in the balloon PTCA
Table 1. Baseline Clinical Characteristics
Stent
(n 5 56)
PTCA
(n 5 54)
Age (yr) 58.3 6 6.8 57.0 6 9.3
Male 48 (86%) 45 (83%)
Previous MI 30 (54%) 45 (83%)
Previous CABG 1 (1.8%) 1 (1.8%)
Diabetes 6 (11%) 5 (9.2%)
Hypertension 22 (39%) 21 (39%)
Smokers 24 (43%) 23 (43%)
Hypercholesterolemia 25 (45%) 16 (30%)
Angina
None 3 (5.3%) 2 (3.7%)
CCS I or II 31 (55%) 34 (56%)
CCS III or IV 18 (32%) 12 (22%)
Unstable angina 4 (7.1%) 6 (11%)
Estimated duration of occlusion (wk) 11.1 6 8.3 11.5 6 8.2
Data presented are mean value 6 SD or number (%) of patients. CABG 5
coronary artery bypass graft surgery; CCS 5 Canadian Cardiovascular Society
angina classification; MI 5 myocardial infarction; PTCA 5 percutaneous
transluminal coronary angioplasty.
Table 2. Baseline Angiographic Characteristics and
Procedural Variables
Stent
(n 5 56)
PTCA
(n 5 54)
Diseased vessels
One 36 (64%) 41 (76%)
Two 18 (32%) 10 (18%)
Three 2 (3.6%) 2 (3.7%)
Occluded artery
LAD 29 (52%) 29 (54%)
LCx 7 (12%) 13 (24%)
RCA 20 (36%) 12 (22%)
Occlusion type
Complete (TIMI grade 0 flow) 35 (62%) 38 (70%)
Functional (TIMI grade 1 flow) 21 (37%) 16 (30%)
LVEF (%) 55.1 6 15.0 55.7 6 13.3
Nominal size of largest balloon (mm) 3.36 6 0.38 3.03 6 0.34*
Maximal inflation pressure (atm) 11.3 6 3.5 7.7 6 2.9*
Postprocedural dissection 3 (5.3%) 17 (31%)†
Implantation of multiple stents 5 (8.9%) —
Another dilated lesion in addition to
occlusion
4 (7.1%) 5 (9.2%)
*p , 0.0001, †p 5 0.0009, stent versus percutaneous transluminal coronary
angioplasty (PTCA). Data presented are mean value or number (%) of patients.
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; RCA 5 right coronary artery; TIMI 5 Thrombolysis in Myocardial
Infarction.
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group, another subtotal lesion was dilated in addition to the
study occlusion.
In the stent group, the maximal balloon diameter and the
maximal balloon pressure were significantly higher than those
used in the balloon PTCA group, a result of increasing use
during the study period of slightly oversized balloons at high
pressure for postimplantation dilation of the stent (16).
Angiographic results. Follow-up angiography was per-
formed at 9.1 6 3.3 months in 97 patients (88%). Angiography
was not repeated in 13 patients; 6 patients in each group
refused the procedure; and 1 patient in the PTCA group died
suddenly before follow-up angiography.
The quantitative coronary angiographic results are shown in
Table 3. Stent implantation resulted in a larger postprocedural
MLD than did PTCA, and this difference was maintained at
follow-up (Fig. 1). Accordingly, the restenosis rate was 32.0%
in the stent group versus 68.1% in the PTCA group. Likewise,
a remarkable difference in the reocclusion rate was observed
(8% in the stent group, 34% in the PTCA group). Late loss was
not significantly different between the two groups, but the loss
index was higher in the PTCA group. This difference was
maintained when only nonoccluded vessels at follow-up were
analyzed.
Stepwise logistic regression analysis identified assignment
to stent implantation as the most important predictor of MLD
at follow-up (p , 0.001). In addition, the presence of diabetes
(p 5 0.01) and the value of postprocedural diameter stenosis
(p 5 0.02) were negatively associated with MLD at follow-up.
Clinical events in-hospital and during follow-up. The clin-
ical outcome of the patients is shown in Table 4. The rate of
target lesion revascularization was significantly higher in the
PTCA group than in the stent group (22% and 5.3%, respec-
tively). Recurrent ischemia, defined as either angina or objec-
tive evidence of ischemia, was significantly more frequent in
patients assigned to PTCA than in those assigned to stent
placement (46% and 14%, respectively). All patients who
underwent a repeat revascularization procedure had recurrent
ischemia.
Stent group. In the stent group, two patients underwent
in-hospital emergency coronary artery bypass graft surgery
because of stent thrombosis. Three patients required repeat
PTCA: One underwent in-hospital PTCA because of stent
thrombosis (this patient subsequently underwent emergency
bypass surgery), and two underwent PTCA during follow-up
(one for symptomatic reocclusion, one for progression of the
disease in another vessel). Five patients with restenosis (one
with total reocclusion) and recurrent ischemia were treated
medically, and nine other patients with restenosis (two with a
total reocclusion) remained asymptomatic.
PTCA group. In the PTCA group, one patient died sud-
denly 8 months after the procedure. Four patients underwent
elective bypass surgery during follow-up (three for symptom-
atic reocclusion, one for progression of the disease in another
vessel). Ten patients with symptomatic restenosis (four with
Table 3. Quantitative Coronary Angiographic Data
Stent
(n 5 56)
PTCA
(n 5 54) p Value
Before procedure
Proximal vessel diam (mm) 3.02 6 0.69 2.92 6 0.48 0.37
After procedure
RD (mm) 3.01 6 0.48 2.92 6 0.55 0.34
MLD (mm) 2.46 6 0.50 1.91 6 0.49 ,0.0001
DS (%) 18.2 6 11.2 34.5 6 10.3 ,0.0001
At follow-up
RD (mm) 2.99 6 0.51 2.85 6 0.48 0.15
MLD (mm) 1.74 6 0.88 0.85 6 0.75 ,0.0001
DS (%) 42.3 6 26.6 69.2 6 26.8 ,0.0001
Restenosis rate (% of pts) 32.0 68.1 0.0008
Reocclusion rate (% of pts) 8.0 34.0 0.0035
Change in MLD
All lesions
Late loss (mm) 0.76 6 0.71 1.06 6 0.80 0.06
Loss index 0.32 6 0.31 0.55 6 0.38 0.002
Only nonoccluded vessels at
follow-up
Late loss (mm) 0.61 6 0.52 0.55 6 0.36 0.54
Loss index 0.26 6 0.24 0.30 6 0.21 0.03
Data presented are mean value 6 SD or percent of patients (pts). DS 5
diameter stenosis; MLD 5 minimal lumen diameter; PTCA 5 percutaneous
transluminal coronary angioplasty; RD 5 reference diameter.
Figure 1. Cumulative distribution function curves of postprocedural
and follow-up MLD in patients assigned to PTCA or stent implanta-
tion.
Table 4. Clinical Events in the Hospital and During Follow-Up and
Length of Hospital Stay
Stent
(n 5 56)
PTCA
(n 5 54)
p
Value
Death 0 1 (1.8%) 0.97
Q wave MI 0 0
CABG 2 (3.6%) 4 (7.4%) 0.74
Repeat PTCA 3 (5.3%) 10 (18%) 0.10
Target lesion revasc 3 (5.3%) 12 (22%) 0.038
Recurrent ischemia 8 (14%) 25 (46%) 0.002
Bleeding and vascular
complications
4 (7.1%) 0 0.11
Length of hospital stay
(days)
11.5 6 6.44 8.7 6 5.54 0.002
Data presented are mean value 6 SD or number (%) of patients. revasc 5
revascularization; other abbreviations as in Table 1.
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total reocclusion) required an elective repeat PTCA during
follow-up. Eighteen patients with restenosis (five with a total
reocclusion) and recurrent ischemia were treated medically,
and seven other patients with restenosis (four with a total
reocclusion) remained asymptomatic.
Other events. Surgical repair of a femoral artery pseudoan-
eurysm was required in four patients assigned to stent implan-
tation, two of whom also received a blood transfusion; no
hemorrhagic complications were observed in the PTCA group.
Discussion
Stenting versus PTCA. The Belgium and Netherland Stent
(BENESTENT) study (17) and Stent Restenosis Study
(STRESS) (18) compared balloon PTCA with the Palmaz-
Schatz coronary stent in selected patients with subtotal steno-
ses and found a larger follow-up MLD and a lower restenosis
rate in the stent group. However, this effect may not apply to
chronic total occlusions because stent implantation in this
lesion subset carries specific limitations, such as difficulty in
assessing lesion length and vessel diameter, which may result in
incomplete coverage of the lesion or incorrect stent expansion.
In addition, a thrombus may be present in total occlusions, and
the flow after recanalization is often slow, generally because of
competitive collateral flow or distal embolization of throm-
botic material. These aspects may favor thrombosis of the
stent.
In the present trial, placement of a Palmaz-Schatz stent
after balloon PTCA of a chronic total occlusion of a coronary
artery was associated with markedly better angiographic results
than those observed after PTCA alone (Table 3). At follow-up,
the mean MLD in the stent group was twice as large as that in
the PTCA group (1.74 vs. 0.85 mm), and the restenosis rate
was half that of the PTCA group (32% vs. 68%). In addition,
a fourfold reduction in the reocclusion rate was observed in
patients assigned to stent implantation (8% vs. 34%). Accord-
ingly, patients treated with a stent experienced a significant
reduction in revascularization procedures and a better symp-
tomatic status during follow-up. The longer hospital stay in
patients assigned to stent implantation was due to institution of
oral anticoagulant therapy. More recently, this strategy has
been abandoned (7,9,16,19,20). Both the angiographic and
clinical results in the present study are similar to those of the
recently published Stenting in Chronic Coronary Occlusions
(SICCO) study (10) despite methodologic differences between
the two studies. In our study, cinefilms were evaluated at a core
laboratory using a single method for quantitative angiography;
in the SICCO trial, angiographic evaluation was performed at
various clinical sites using different methods.
In the present study, the restenosis rate in the PTCA group
(68%) appears to be higher than previously reported (3–5) but
is comparable to the 74% observed in the SICCO trial (10).
Mechanisms of benefit. Two recent studies (4,5) compared
the midterm renarrowing process after PTCA of chronic total
occlusions or subtotal stenoses by means of quantitative coro-
nary angiography. These studies showed that the higher inci-
dence of restenosis in recanalized total occlusions relates
mainly to the higher rate of reocclusion at follow-up. Total
occlusions demonstrated a reocclusion rate of 19% in both
studies, whereas only 5% (4) or 7% (5) of subtotal stenoses
treated by PTCA were found to be occluded at follow-up.
When patients with reocclusion were excluded from analysis,
the difference in restenosis between total occlusions and
subtotal stenoses was no longer significant. An early reocclu-
sion after successful PTCA may be clinically silent because of
preexistent collateral flow and may be detected only at follow-
up, contributing to the increased restenosis rate.
According to the currently available evidence, late resten-
osis is mainly due to vascular remodeling and neointimal
proliferation; however, early reocclusion may share the mech-
anisms of post-PTCA abrupt closure—namely dissection, elas-
tic recoil and thrombus formation. Another factor predispos-
ing to early reocclusion may be a subintimal pathway of
recanalization (21) as opposed to recanalization through the
true lumen. This false lumen may be more prone to recoil or
thrombotic occlusion.
Stent implantation may reduce early reocclusions by pre-
venting elastic recoil and sealing intimal dissection. The opti-
mization of lumen geometry may also increase the flow and
reduce shear stress, which in turn may decrease platelet
aggregation and thrombus formation, outweighing the intrinsic
thrombogenicity of the stent.
In addition to prevention of reocclusion, the beneficial
effect of stent implantation on late MLD is most probably
related to the larger initial diameter provided by the stent; loss
during follow-up is not significantly different between the two
groups.
It is noteworthy that in our patients, the mean late loss after
stent implantation was 0.76 mm (Table 3), a value similar to
that observed in the BENESTENT (0.65 mm) (17) and
STRESS trials (0.74 mm) (18), whereas the mean late loss after
PTCA was higher in our study (1.06 mm) than in the BENE-
STENT and STRESS trials (0.32 and 0.38 mm, respectively).
In other words, balloon PTCA of chronic total occlusions is
associated with a higher late loss than that for subtotal stenoses
(4,5), but this difference between chronic total occlusions and
subtotal stenoses is not evident after stent implantation.
Study limitations. As in most multicenter trials, our study
patients were selected according to patient or physician con-
sent, operator evaluation of each individual case and the
likelihood of patient follow-up. Therefore, our patients may
not be completely representative of the overall population of
patients with chronic coronary occlusion.
The relatively small sample size may be an important
limitation because the study does not have the power to detect
potential differences between the two study groups with regard
to infrequent clinical events, such as death, myocardial infarc-
tion or major bleeding.
Because the patients in the stent group, but not those in the
PTCA group, followed an anticoagulant regimen for 1 month,
a potential effect of this therapy on the restenosis or reocclu-
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sion rate cannot be ruled out. Other clinical studies (22–26)
have excluded any effect of anticoagulant therapy on restenosis
after PTCA. Additionally, observational data (7,9) on stent
implantation in chronic total occlusions without subsequent
anticoagulation showed low restenosis and reocclusion rates,
comparable to that observed after stenting followed by antico-
agulant therapy.
Because early angiography was performed only for recur-
rent symptoms, neither the early reocclusion rate after PTCA
nor the thrombosis rate after stenting could be ascertained. In
both treatment groups, the reocclusion rate at follow-up could
not represent the early reocclusion rate because early throm-
bosis may result in spontaneous thrombolysis and, conversely,
late reocclusion may result from progressive restenosis.
In the present study, the elective stent implantation was
performed after successful balloon PTCA. In subtotal stenoses,
nonelective stenting for abrupt or threatened closure or a
suboptimal result carries a higher risk of acute complications
and restenosis than does elective stenting (27–29). Thus, the
observed results may not apply to nonelective stent implanta-
tion motivated by early recoil, occlusive dissection or abrupt
reocclusion after PTCA of chronic total occlusions.
In recent years, the technique of stent deployment has
evolved substantially. Intravascular ultrasound observations
have shown (30) that high pressure balloon dilation may
improve the apposition of the stent to the vessel wall and
provide a larger lumen. This in turn may decrease the risk of
stent thrombosis (31), as well as the restenosis rate, the latter
being inversely related to the acute lumen diameter (18). In
addition, therapy with ticlopidine and aspirin has been shown
(19) to reduce the incidence of stent thrombosis compared
with oral anticoagulant therapy. In our study, only 18% of
patients underwent dilation of the stent at high pressure
($16 atm), and all patients in the stent group received
conventional anticoagulant therapy. Therefore, it remains to
be determined whether these technical advances may further
improve the results of stenting in chronic total occlusions. In
addition, the results of our study cannot be extrapolated to
other stent types.
Conclusions. Implantation of a Palmaz-Schatz stent after
successful PTCA of a chronic total occlusion results in a larger
MLD at follow-up and decreases the restenosis and reocclu-
sion rates. Accordingly, patients treated with a stent experi-
ence a significant reduction of repeat revascularization proce-
dures and a better symptomatic status during the follow-up.
Thus, Palmaz-Schatz stent implantation could be the preferred
treatment option in selected patients with occluded coronary
arteries that can be recanalized with PTCA.
We are grateful to Francesco Copello, MD, PhD, Genoa, for statistical analysis,
and Eric Bates, MD, FACC, Ann Arbor, for helpful advice.
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